Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
- 04.08.2017
- ORIGINAL ARTICLE
Erschienen in:
- Verfasst von
- Masanori Asakura
- Jiyoong Kim
- Hiroshi Asanuma
- Toshimitsu Hamasaki
- Kengo Tsukahara
- Yorihiko Higashino
- Tetsuya Ishikawa
- Yasuharu Nakama
- Shinji Koba
- Yasuyuki Maruyama
- Mitsuru Tsujimoto
- Hideo Himeno
- Takanori Ohkusa
- Susumu Fujino
- Makoto Shimizu
- Tsutomu Endo
- Shunichi Yoda
- Takahiro Muroya
- Toyoaki Murohara
- Nobuyuki Ohte
- Hiroshi Suzuki
- Tohru Kohno
- Kazuki Fukui
- Takaaki Shiono
- Hiroyuki Takase
- Hiroyasu Uzui
- Yoshiyuki Nagai
- Yuji Hashimoto
- Shuntaro Ikeda
- Sumio Mizuno
- Koichi Tamita
- Masashi Fujita
- Kazuo Satake
- Yoshihiko Kinoshita
- Tatsuya Nunohiro
- Satoru Sakagami
- Jitsuo Higaki
- Isao Morii
- Reimin Sawada
- Yoshikazu Hiasa
- Tomohiko Shigemasa
- Makoto Nakahama
- Masataka Sata
- Osamu Doi
- Tetsuro Ueda
- Takahisa Yamada
- Takayoshi Yamanouchi
- Hajime Yamaguchi
- Yukiko Morita
- Hideki Hayashi
- Masafumi Kitakaze
- ABC investigators
- Erschienen in
- Cardiovascular Drugs and Therapy | Ausgabe 4/2017
Abstract
Purpose
We evaluated the effects of an alpha-glucosidase inhibitor, voglibose, on cardiovascular events in patients with a previous myocardial infarction (MI) and impaired glucose tolerance (IGT).
Methods
This prospective, randomized, open, blinded-endpoint study was conducted in 112 hospitals and clinics in Japan in 3000 subjects with both previous MI and IGT receiving voglibose (0.6 mg/day, n = 424) or no drugs (n = 435) for 2 years. The Data and Safety Monitoring Board (DSMB) recommended discontinuation of the study in June 2012 after an interim analysis when the outcomes of 859 subjects were obtained. The primary endpoint was cardiovascular events including cardiovascular death, nonfatal MI, nonfatal unstable angina, nonfatal stroke, and percutaneous coronary intervention/coronary artery bypass graft. Secondary endpoints included individual components of the primary endpoint in addition to all-cause mortality and hospitalization due to heart failure.
Results
The age, ratio of males, and HbA1C were 65 vs. 65 years, 86 vs. 87%, and 5.6 vs. 5.5% in the groups with and without voglibose, respectively. Voglibose improved IGT; however, Kaplan–Meier analysis showed no significant between-group difference with respect to cardiovascular events [12.5% with voglibose vs. 10.1% without voglibose for the primary endpoint (95% confidence interval, 0.82–1.86)]; there were no significant differences in secondary endpoints.
Conclusion
Although voglibose effectively treated IGT, no additional benefits for cardiovascular events in patients with previous MI and IGT were observed. Voglibose may not be a contributing therapy to the secondary prevention in patients with MI and IGT.
Trial Registration
Clinicaltrials.gov number: NCT00212017
Anzeige
- Titel
- Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
- Verfasst von
-
Masanori Asakura
Jiyoong Kim
Hiroshi Asanuma
Toshimitsu Hamasaki
Kengo Tsukahara
Yorihiko Higashino
Tetsuya Ishikawa
Yasuharu Nakama
Shinji Koba
Yasuyuki Maruyama
Mitsuru Tsujimoto
Hideo Himeno
Takanori Ohkusa
Susumu Fujino
Makoto Shimizu
Tsutomu Endo
Shunichi Yoda
Takahiro Muroya
Toyoaki Murohara
Nobuyuki Ohte
Hiroshi Suzuki
Tohru Kohno
Kazuki Fukui
Takaaki Shiono
Hiroyuki Takase
Hiroyasu Uzui
Yoshiyuki Nagai
Yuji Hashimoto
Shuntaro Ikeda
Sumio Mizuno
Koichi Tamita
Masashi Fujita
Kazuo Satake
Yoshihiko Kinoshita
Tatsuya Nunohiro
Satoru Sakagami
Jitsuo Higaki
Isao Morii
Reimin Sawada
Yoshikazu Hiasa
Tomohiko Shigemasa
Makoto Nakahama
Masataka Sata
Osamu Doi
Tetsuro Ueda
Takahisa Yamada
Takayoshi Yamanouchi
Hajime Yamaguchi
Yukiko Morita
Hideki Hayashi
Masafumi Kitakaze
ABC investigators
- Publikationsdatum
- 04.08.2017
- Verlag
- Springer US
- Erschienen in
-
Cardiovascular Drugs and Therapy / Ausgabe 4/2017
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241 - DOI
- https://doi.org/10.1007/s10557-017-6740-3
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
